These findings have more recently been confirmed in glioblastoma primary cultures; treating primary cultures of gliobalstoma cells with natural or synthetic PPARγ  ligands  decreases the expression of markers of undifferentiated stages, such as CD133, nestin and fibronectin, while increasing the expression of differentiation markers such as A2B5, GFAP, β-catenin, and N-cadherin. The gene discussed is PPARG; the disease is glioblastoma.